Presented by
Management Forum
The nasal cavity is an established pathway to treat local diseases as well as systemic conditions using small molecules. As the pharmaceutical industry shifts towards targeted biologics, the nasal cavity is also an attractive target for delivery of peptides, monoclonal antibodies, nucleic acids and stem cells. This is an ideal opportunity to hear from experts in the field of nasal drug delivery who will address topics such as: challenges associated with formulation, barriers to cell penetration and absorption, the pros and cons for liquid versus powder formulations, and strategies for maintaining stability and prolonging retention in the nasal cavity.
★★★★★ "Very clear and informative!"
The nasal cavity is an established pathway to treat local diseases as well as systemic conditions using small molecules. As the pharmaceutical industry shifts towards targeted biologics, the nasal cavity is also an attractive target for delivery of peptides, monoclonal antibodies, nucleic acids and stem cells. For example, an intranasal mAb formulation is in phase 1 clinical trials for progressive Multiple Sclerosis.
This course will address the challenges associated with formulation and clinical trial manufacture of biologics for delivery to the nasal cavity. The course will also highlight barriers to cell penetration and absorption and identification of an ideal target product profile.
The pros and cons for liquid versus powder formulations will be discussed. In addition, the course will focus on strategies for maintaining stability and prolonging retention in the nasal cavity. Device selection for preclinical and clinical studies using predictive tools such as nasal casts will be presented.
Finally, the session will help prepare the audience with manufacturing strategies for clinical trials with a nasally administered biologic.
This course is of our range of Medical Devices training courses - now also including Medical Devices Cyber Security training to help improve your data security.
Very clear and informative!
Oct 10 2023
Serge PAMPFER
CEO, Maedia
Jun 6 2023
The webinar was an excellent overview and insight into an emerging field - good balance of market intel and technical detail.
Eleanor Catherine Canipa
Senior Business Development Manager, Nanopharm (an Aptar Company)
United States of America
United Kingdom
Israel
Italy
Argentina
Germany
Sweden
Australia
Belgium
Canada
Denmark
Switzerland
Multiple colleagues? See above for details of our discounts for 2, 3, or 4 delegates. For more, talk to one of our training experts to discuss how to: